The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Targeting Energy Metabolism in Mycobacterium tuberculosis , a New Paradigm in Antimycobacterial Drug Discovery
Open accessAbstract
Drug-resistant mycobacterial infections are a serious global health challenge, leading to high mortality and socioeconomic burdens in developing countries worldwide. New innovative approaches, from identification of new targets to discovery of novel chemical scaffolds, are urgently needed. Recently, energy metabolism in mycobacteria, in particular the oxidative phosphorylation pathway, has emerged as an object of intense microbiological investigation and as a novel target pathway in drug discovery. New classes of antibacterials interfering with elements of the oxidative phosphorylation pathway are highly active in combating dormant or latent mycobacterial infections, with a promise of shortening tuberculosis chemotherapy. The regulatory approval of the ATP synthase inhibitor bedaquiline and the discovery of Q203, a candidate drug targeting the cytochrome bc 1 complex, have highlighted the central importance of this new target pathway. In this review, we discuss key features and potential applications of inhibiting energy metabolism in our quest for discovering potent novel and sterilizing drug combinations for combating tuberculosis. We believe that the combination of drugs targeting elements of the oxidative phosphorylation pathway can lead to a completely new regimen for drug-susceptible and multidrug-resistant tuberculosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genes required for mycobacterial growth defined by high density mutagenesis
Sassetti, C. M., Boyd, D. H., & Rubin, E. J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03425.x · Cited by 2,544
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 1×
“throughput screening efforts have mainly yielded classes of small-molecule inhibitors active on either ATP synthase (8, 26) or the cytochrome bc1 complex (23, 25, 26).”
BackgroundDiarylquinolines target subunit c of mycobacterial ATP synthase
Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I., Guillemont, J., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio884 · Cited by 547
Self-citationIntracellular Mycobacterium tuberculosis Exploits Host-derived Fatty Acids to Limit Metabolic Stress
Lee, W., VanderVen, B. C., Fahey, R. J., & Russell, D. G. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.445056 · Cited by 424
Fumarate Reductase Activity Maintains an Energized Membrane in Anaerobic Mycobacterium tuberculosis
Watanabe, S., Zimmermann, M., Goodwin, M. B., Sauer, U., Barry, C. E., & Boshoff, H. I. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002287 · Cited by 246
Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria
Cook, G. M., Hards, K., Vilchèze, C., Hartman, T., & Berney, M. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0015-2013 · Cited by 212
Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB
Abrahams, K. A., Cox, J. A. G., Spivey, V. L., Loman, N. J., Pallen, M. J., Constantinidou, C., Fernández, R., Alemparte, C., Remuiñán, M. J., Barros, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052951 · Cited by 177
Characterization of the cydAB -Encoded Cytochrome bd Oxidase from Mycobacterium smegmatis
Kana, B. D., Weinstein, E. A., Avarbock, D., Dawes, S. S., Rubin, H., & Mizrahi, V. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.24.7076-7086.2001 · Cited by 153
The F 1 F o -ATP Synthase of Mycobacterium smegmatis Is Essential for Growth
Tran, S. L., & Cook, G. M. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.14.5023-5028.2005 · Cited by 116
Cited by
Adolph, C., McNeil, M. B., & Cook, G. M. (2022) · mBio · doi:10.1128/mbio.01672-22 · Cited by 32
Structure of mycobacterial respiratory complex I
Liang, Y., Plourde, A., Bueler, S. A., Liu, J., Brzezinski, P., Vahidi, S., & Rubinstein, J. L. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214949120 · Cited by 31
Targeting de novo purine biosynthesis for tuberculosis treatment
Lamprecht, D. A., Wall, R. J., Leemans, A., Truebody, B., Sprangers, J., Fiogbe, P., Davies, C., Wetzel, J., Daems, S., Pearson, W., et al. (2025) · Nature · doi:10.1038/s41586-025-09177-7 · Cited by 24
Self-citationStructure of Mycobacterial NDH-2 Bound to a 2-Mercapto-Quinazolinone Inhibitor
Liang, Y., Bueler, S. A., Cook, G. M., & Rubinstein, J. L. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00049 · Cited by 13
The Mycobacterium smegmatis bd -II terminal oxidase employs a carboxylate shift mechanism
Kovalova, T., Janczak, M., Gamiz-Hernandez, A. P., Lundin, D., Sharma, S., Vilhjálmsdóttir, J., Sjöstrand, D., Kaila, V. R. I., Högbom, M., & Ädelroth, P. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2515348123 · Cited by 1
Metadata
- Authors
- Bald, D., Villellas, C., Lu, P., & Koul, A.
- Venue
- mBio
- Publisher
- American Society for Microbiology
- Published
- 2017-05-03
- Volume
- 8
- Issue
- 2
- ISSN
- 2150-7511 (ISSN-L)
- 2161-2129
- OpenAlex
- W2607441147
- Cited by
- 219
- References
- 9
- FWCI
- 16.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Energy Metabolism in Mycobacterium tuberculosis , a New Paradigm in Antimycobacterial Drug Discovery. https://app.cochat.ai/papers/10.1128/mbio.00272-17
- The paper
- Bald, D., Villellas, C., Lu, P., & Koul, A. (2017). Targeting Energy Metabolism in Mycobacterium tuberculosis , a New Paradigm in Antimycobacterial Drug Discovery. mBio. https://doi.org/10.1128/mbio.00272-17
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.